SDL Announces General Availability of SDL Multilingual Submission Management

Solution Developed Specifically for Global Multilingual Regulatory Submissions

Maidenhead, UK
10/24/2017 11:42:24 AM

SDL (LSE: SDL) has announced the availability of SDL Multilingual Submission Management (MSM), a web-based platform that enables biopharmaceutical firms to globally automate the submission of multilingual marketing authorization applications to regulatory authorities across 100+ languages and markets. 

Operating in one of the most demanding and highly regulated environments, pharmaceutical organizations face the constant challenge of filing, updating and maintaining medicinal product information globally. High standards demanded by local regulatory agencies during the submissions process – which varies by country – puts enormous pressure on firms to ensure every element of their application is flawless. Formatting and translation errors can delay timelines by weeks or even months. 

SDL MSM enables these organizations to overcome all the multilingual challenges associated with regulatory labelling and submission, providing the industry’s first dedicated platform for centrally managing this process globally. Based on market validated technologies that have helped many pharmaceutical organizations manage their global regulatory labelling submissions for the past decade, SDL MSM also combines a rich set of features that make it simple to manage the complete submission process from a single dashboard. 

“Submitting local language documents for regulatory approval with one regulatory agency is difficult enough – let alone across dozens of countries where documents need to be translated, reformatted, and orchestrated in a timely fashion,” said Kaarin Gordon, SVP of global life sciences, SDL. “Our proven success in this area for the past decade – combined with the exciting new web-based features that SDL MSM offers – make it a powerful platform to overcome one of the biggest burdens for international regulatory affairs departments.” 

Announced at the Global Pharmaceutical Regulatory Affairs Summit, Prague, SDL MSM offers easier, faster and lower cost deployment – with greater availability of services.

Get in touch
Contact us

About RWS

RWS Holdings plc is a unique, world-leading provider of technology-enabled language, content and intellectual property services. Through content transformation and multilingual data analysis, our combination of AI-enabled technology and human expertise helps our clients to grow by ensuring they are understood anywhere, in any language.


Our purpose is unlocking global understanding. By combining cultural understanding, client understanding and technical understanding, our services and technology assist our clients to acquire and retain customers, deliver engaging user experiences, maintain compliance and gain actionable insights into their data and content.


Over the past 20 years we’ve been evolving our own AI solutions as well as helping clients to explore, build and use multilingual AI applications. With 40+ AI-related patents and more than 100 peer-reviewed papers, we have the experience and expertise to support clients on their AI journey.


We work with over 80% of the world’s top 100 brands, more than three-quarters of Fortune’s 20 ‘Most Admired Companies’ and almost all of the top pharmaceutical companies, investment banks, law firms and patent filers. Our client base spans Europe, Asia Pacific, Africa and North and South America. Our 65+ global locations across five continents service clients in the automotive, chemical, financial, legal, medical, pharmaceutical, technology and telecommunications sectors.


Founded in 1958, RWS is headquartered in the UK and publicly listed on AIM, the London Stock Exchange regulated market (RWS.L). 


For further information, please visit: www.rws.com.


© 2023 All rights reserved. Information contained herein is deemed confidential and the proprietary information of RWS Group*.
*RWS Group shall mean RWS Holdings plc for and on behalf of its affiliates and subsidiaries.